Ana Slaughter
Impact in
-
- Multiple Myeloma Research and Treatments
-
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Hematology 19
- Multiple Myeloma Research and Treatments 19
- Chronic Myeloid Leukemia Treatments 3
-
- Protein Degradation and Inhibitors 11
- Glycosylation and Glycoproteins Research 2
- Histone Deacetylase Inhibitors Research 1
- Co-authors
- Philippe Moreau (8 shared papers)Jordan M. Schecter (8 shared papers)Kwee Yong (5 shared papers)Carolina Lonardi (12 shared papers)Binod Dhakal (7 shared papers)Nikoletta Lendvai (9 shared papers)Hermann Einsele (8 shared papers)Mohamed H. Zaki (7 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Blood (4 papers)Haematologica (2 papers)European Journal of Cancer (1 paper)Blood Advances (1 paper)
- Partner nations
- GermanySpainUnited States
In The Last Decade
Ana Slaughter
17 papers receiving 49 citations
Peers
Comparison fields: 5 of 17
- Hematology 38
- Oncology 33
- Molecular Biology 33
- Genetics 4
- Immunology 4
Countries citing papers authored by Ana Slaughter
This map shows the geographic impact of Ana Slaughter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Slaughter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Slaughter more than expected).
Fields of papers citing papers by Ana Slaughter
This network shows the impact of papers produced by Ana Slaughter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Slaughter. The network helps show where Ana Slaughter may publish in the future.
Co-authors
The 25 scholars most cited alongside Ana Slaughter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 20 | |
| 2 | 2014 | 4 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 3 | |
| 5 | 2016 | 3 | |
| 6 | 2015 | 3 | |
| 7 | 2024 | 2 | |
| 8 | 2024 | 2 | |
| 9 | 2022 | 2 | |
| 10 | THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA | 2015 | 1 |
| 11 | OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY | 2015 | 1 |
| 12 | 2025 | 1 | |
| 13 | 2015 | 1 | |
| 14 | 2024 | 1 | |
| 15 | 2014 | 1 | |
| 16 | 2022 | 1 | |
| 17 | 2014 | 1 | |
| 18 | 2024 | 0 | |
| 19 | 2024 | 0 | |
| 20 | 2023 | 0 |
About Ana Slaughter
Ana Slaughter is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Pathology and Forensic Medicine, having authored 20 papers that have together received 50 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (11 papers), Cancer Treatment and Pharmacology (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), CAR-T cell therapy research (2 papers), Glycosylation and Glycoproteins Research (2 papers), Histone Deacetylase Inhibitors Research (1 paper) and Chronic Lymphocytic Leukemia Research (1 paper). The work is most often cited by research in Hematology (38 citations), Oncology (33 citations), Molecular Biology (33 citations), Genetics (4 citations) and Immunology (4 citations). Ana Slaughter has collaborated with scholars based in Germany, Spain and United States. Frequent co-authors include Philippe Moreau, Jordan M. Schecter, Kwee Yong, Carolina Lonardi, Binod Dhakal, Nikoletta Lendvai, Hermann Einsele, Mohamed H. Zaki, Simon J. Harrison and Enrique M. Ocio. Their work appears in journals such as Journal of Clinical Oncology, Blood, Haematologica, European Journal of Cancer and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.